Contract analysis

I. PURPOSE AND EXECUTIVE SUMMARY The purpose of this memorandum is to memorialize the closure of Matter 1018-00009 following the execution of an IRS Form 906 Closing Agreement on March 29, 2024, formally resolving the IRS Large Business & International Division's multi-year transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC"), EIN 22-3741856, for tax years 2017, 2018, 2019, and 2020. This memorandum

II. ENGAGEMENT OVERVIEW A. Retention and Staffing Calderwood & Harkness LLP ("C&H") was retained by Penterra Pharmaceuticals Corp. to defend PPC against the IRS's transfer pricing examination for tax years 2017 through 2020. The engagement letter was executed on June 2, 2022, between Calderwood & Harkness LLP and PPC. Prior to execution, a draft engagement letter was circulated to Marcus Whitfield, Vice President of

III. BACKGROUND — CLIENT STRUCTURE AND TRANSFER PRICING POSITIONS A. Corporate Structure The relevant corporate structure for purposes of the transfer pricing examination is as follows: Penterra Pharmaceuticals Corp. ("PPC") — The U.S. parent entity. PPC is a Delaware corporation publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. PPC is headquartered at 2200 Independence Boulevard, Princeton Jun

1. A platform contribution transaction ("PCT") payment of $312 million, paid as a lump sum by PBI to PPC on July 1, 2012, representing a buy-in to the pre-existing IP portfolio, which consisted primarily of clinical-stage and approved oncology compounds.

2. Ongoing cost-sharing payments representing PBI's share of the annual intangible development costs ("Coss") in the shared R&D cost pool. PPC's reported cost-sharing ratios for the tax years under examination, which were determined based on reasonably anticipated benefit ("RAB") projections, were as follows: The gradual increase in PBI's cost-sharing percentage over the examination period reflected the projected gro

IV. EXAMINATION HISTORY AND TIMELINE A. Examination Opening and IDR Phase The IRS opened its examination of PPC's transfer pricing positions on May 16, 2022, with the issuance of an initial contact letter (Letter 2205-A) from the LB&I Northeast Transfer Pricing Practice. The examination was assigned Team ID LB&I-NE-TP-2022-00641 and was supervised by Supervisory Revenue Agent Gerald Meskill. Calderwood & Harkness's e

I. Settlement and Closing — March 2024 On March 15, 2024, Appeals Officer Castañeda communicated a settlement offer to Calderwood & Harkness. The proposed settlement called for a total adjustment of $47.6 million across all four tax years, with full abatement of the proposed IRC § 6662(e) substantial valuation misstatement penalty. On March 18, 2024, Leonard Cross and Sylvia Hartwell prepared a settlement offer analy

V. IRS's PROPOSED ADJUSTMENTS — SUMMARY The IRS's proposed adjustments, as set forth in the NOPA issued on October 12, 2023, are summarized below. A. CSA Cost-Sharing Ratio Adjustments The IRS proposed increasing PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points per year. The IRS's position was that PPC's reasonably anticipated benefit projections understated the value attributable to U.S.-sour

VI. DEFENSE STRATEGY AND KEY DELIVERABLES — SUMMARY A. Legal Framework The defense strategy was grounded in the following legal authorities: • IRC § 482 — Allocation of income and deductions among controlled entities to clearly reflect income. • IRC § 367(d) — Outbound transfers of intangible property to related foreign corporations. • Treasury Regulation § 1.482-4 — Methods to determine taxable income in connection

1. IRC § 482 arm's-length standard and the best method rule under Treasury Regulation § 1.482-1(d).

2. Qualified cost-sharing arrangement regulatory requirements under Treasury Regulation § 1.482-7.

3. Arm's-length royalty rate analysis under Treasury Regulation § 1.482-4.

4. The economic substance doctrine and the DEMPE framework.

5. Penalty protection and reasonable cause under IRC § 6662(e), including the contemporaneous documentation requirements of § 6662(e)(3)(B).

6. Tax Cuts and Jobs Act ("TCJA") impact — analysis of the transition from the 35% corporate rate applicable to TY 2017 to the 21% rate for TY 2018–2020, including GILTI (IRC § 951A) and BEAT (IRC § 59A) implications.

7. IRC § 367(d) outbound IP transfer considerations.

8. OECD Transfer Pricing Guidelines as persuasive authority in U.S. transfer pricing disputes.

9. Analysis of Altera Corp. v. Commissioner and Harborview Corporation, Inc. v. Commissioner.

10. Correlative adjustments under Treasury Regulation § 1.482-1(g).

11. Competent authority procedures and mutual agreement procedures under the U.S.-Ireland Income Tax Treaty.

12. IRS IDR enforcement procedures and taxpayer rights.

13. IRS Appeals procedures under Revenue Procedure 2015-41.

VII. SETTLEMENT TERMS — FINAL RESOLUTION A. Settlement Adjustment The settlement reached with IRS Appeals provides for a total adjustment to PPC's taxable income of $47.6 million across all four tax years under examination. This amount represents 12.51% of the IRS's proposed net adjustment of $380.4 million. The adjustment is allocated across the tax years as follows: B. Tax Due The federal income tax due on the $47.

VIII. FINANCIAL SUMMARY — PROFESSIONAL FEES AND TOTAL COST A. Calderwood & Harkness LLP Total legal fees billed by Calderwood & Harkness LLP through the close of the matter were $5,837,420. The billing rates applicable at the commencement of the engagement in 2022 were as follows: Billing rates were adjusted annually for 2023 and 2024 in accordance with the firm's standard rate adjustment schedule and the terms of th

IX. ANCILLARY MATTERS AND POST-SETTLEMENT ACTIONS A. FIN 48 / ASC 740-10 Reserve Impact PPC maintained a FIN 48 reserve (ASC 740-10 reserve for uncertain tax positions) related to its Irish IP structure and transfer pricing positions. The reserve was monitored and updated throughout the engagement as follows: • Pre-settlement FIN 48 reserve: $62.4 million. This reserve, established prior to the engagement, reflected

1. Initial update (September 2022): Prepared at the outset of the engagement to reflect the commencement of the IRS examination and the potential range of outcomes.

2. Post-NOPA update (November 2023): Revised following the issuance of the NOPA to incorporate the IRS's specific proposed adjustments.

3. Post-settlement update (March 2024): Finalized following the execution of the Closing Agreement. Correspondence supporting PPC's FIN 48 reserve positions was provided to Crestfield & Associates (Martin Ogilvy) on September 20, 2022 and November 20, 2023, to assist Crestfield in its evaluation of the reserve for financial statement and audit purposes. B. SEC Disclosure Considerations An analysis memorandum was prep

I. Irish Tax Consequences Leila Nazari coordinated with Ciarán Thornbury at Thornbury & Keogh on March 20, 2024, regarding the potential Irish tax impact of the U.S. settlement on PBI's Irish tax position. The coordination addressed the effect, if any, of the U.S. § 482 adjustment on PBI's taxable trading income in Ireland, the implications for PBI's Knowledge Development box claims at the 6.25% rate, and the potenti

X. GOING-FORWARD RECOMMENDATIONS A. Transfer Pricing Documentation Enhancement On April 15, 2024, Leonard Cross and Sylvia Hartwell issued an advisory memorandum to PPC recommending specific enhancements to PPC's transfer pricing documentation practices, cost-sharing calculations, and PBI substance documentation for tax years 2021 forward. The memorandum identified areas where PPC's contemporaneous documentation coul